| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 136.80 | -0.24 (-0.18%) | 83.83 - 138.50 | 1.4 million (Above Avg) |
Market data as of 4:00PM 05/16/12. Quotes are delayed by at least 15 min.
| Open | 137.77 |
|---|---|
| Previous Close | 137.04 |
| Day's Range | 136.19 - 138.50 |
| Market Cap | 32.8B |
| Avg Volume (10 Day) | 1.2M |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Neutral |
|---|---|
| Avoids excess debt? | Neutral |
| Converting sales to profits? | Neutral |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Neutral |
| Sells at 25% discount to intrinsic value? | Neutral |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Neutral |
|---|---|
| Room to increase dividends? | Neutral |
| Increased earnings over time? | Neutral |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Neutral |
| Have investors caught on? | Neutral |
| Has support of institutional investors? | Neutral |
| Has sufficient liquidity? | Neutral |
RBCC, Amarantus Move Forward with Joint Venture Discussions
Business Wire - Wednesday 05/16/2012 5:00 AM ET
New AVONEX® Dosing Innovations for People with Multiple Sclerosis Now Available in US
Business Wire - Monday 05/14/2012 8:00 AM ET
RBCC Partner n3D Makes Waves With Bio-Assembler
Business Wire - Monday 05/14/2012 5:00 AM ET
RBCC Partner n3D Explores New Business Opportunities at Biomedical Conference
Business Wire - Friday 05/11/2012 5:00 AM ET
Les autorités réglementaires américaines et de l'UE acceptent la demande de mise sur le marché du BG-12 par voie orale
Business Wire - Wednesday 05/09/2012 7:21 PM ET
US and EU Regulatory Authorities Accept Oral BG-12 Marketing Applications for Review
Business Wire - Wednesday 05/09/2012 4:05 PM ET
RBCC: Global Scientific Community Embraces New Parkinson’s Therapy
Business Wire - Thursday 05/03/2012 5:00 AM ET
Biogen Idec to Present at the Deutsche Bank 37th Annual Healthcare Conference
Business Wire - Wednesday 05/02/2012 5:22 PM ET
| BIIB | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | -- | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | -- |
| Company | Last | Change |
|---|
Data is delayed by at least 15 min.